JP2011502165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011502165A5 JP2011502165A5 JP2010532246A JP2010532246A JP2011502165A5 JP 2011502165 A5 JP2011502165 A5 JP 2011502165A5 JP 2010532246 A JP2010532246 A JP 2010532246A JP 2010532246 A JP2010532246 A JP 2010532246A JP 2011502165 A5 JP2011502165 A5 JP 2011502165A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- seq
- human subject
- polypeptide
- polynucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccines Drugs 0.000 claims 18
- 241000894006 Bacteria Species 0.000 claims 10
- 229920000023 polynucleotide Polymers 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 9
- 230000028993 immune response Effects 0.000 claims 5
- 230000002163 immunogen Effects 0.000 claims 5
- 210000003495 Flagella Anatomy 0.000 claims 4
- 230000002708 enhancing Effects 0.000 claims 4
- 229960001212 BACTERIAL VACCINES Drugs 0.000 claims 2
- 241000607142 Salmonella Species 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 102100013137 CD40 Human genes 0.000 claims 1
- 101710040446 CD40 Proteins 0.000 claims 1
- 241000588722 Escherichia Species 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims 1
- 206010039447 Salmonellosis Diseases 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 244000144977 poultry Species 0.000 claims 1
- 108091005683 transmembrane proteins Proteins 0.000 claims 1
- 102000035402 transmembrane proteins Human genes 0.000 claims 1
Claims (17)
- fliCポリペプチドをコードする第一のポリヌクレオチド配列およびCD154ポリペプチドをコードする第二のポリヌクレオチド配列を含むワクチンであって、前記CD154ポリペプチドがCD40と結合することができ、前記CD154ポリペプチドが50未満のアミノ酸を有しさらに配列番号:8のアミノ酸140−149またはそのホモローグを含む、前記ワクチン。
- fliCポリペプチドが配列番号:1、配列番号:2、配列番号:10、配列番号:11、配列番号:12、配列番号:１の免疫原性フラグメント、配列番号:2の免疫原性フラグメント、配列番号:10の免疫原性フラグメント、配列番号:11の免疫原性フラグメント、または配列番号:12の免疫原性フラグメントである、請求項1に記載のワクチン。
- CD154ポリペプチドが配列番号:3、配列番号:4、配列番号:5、配列番号:6、配列番号:7を含む、請求項1または2に記載のワクチン。
- ワクチンが細菌性ワクチンである、請求項1−3のいずれかに記載のワクチン。
- 細菌がfliCポリペプチドおよびCD154ポリペプチドの少なくとも1つをその表面に含む、請求項4に記載のワクチン。
- 細菌が、サルモネラ属（Salmonella）の種、エシェリキア属（Escherichia）の種、バシルス属の種（Bacillus）およびラクトバシルス属（Lactobacillus）の種から成る群から選択される、請求項4または5に記載のワクチン。
- 第一のポリヌクレオチドおよび第二のポリヌクレオチドの少なくとも1つがトランスメンブレンタンパク質の外部部分をコードするポリヌクレオチド配列に挿入される、請求項1から6のいずれかに記載のワクチン。
- ワクチンが第一のポリヌクレオチド配列の2つ以上のコピー、第二のポリヌクレオチド配列の2つ以上のコピー、又は、その両方を含む、請求項1から７のいずれかに記載のワクチン。
- 第一のポリヌクレオチド配列が第二のポリヌクレオチド配列とインフレームで連結される、請求項1から8のいずれかに記載のワクチン。
- サルモネラ・エンテリティディス13Aの変種を含むワクチンであって、前記サルモネラがfliCポリペプチドをコードする外因性の第一のポリヌクレオチド配列を含む、前記ワクチン。
- 非ヒト対象に、請求項１〜１０のいずれかに記載のワクチンを投与する工程を含む、非ヒト対象で鞭毛細菌に対して免疫応答を強化する方法であって、前記ワクチンが前記鞭毛細菌に対する非ヒト対象の免疫応答を強化するために有効な量で投与される、前記免疫応答を強化する方法。
- ワクチンが細菌性ワクチンベクターであり、該細菌が経口、鼻内、非経口および卵内から成る群から選択される方法によって投与される、請求項１１に記載の方法。
- 免疫応答の強化が抗体応答の強化又はT細胞応答の強化を含む、請求項１１又は１２に記載の方法。
- 非ヒト対象が家禽の種のメンバー又は非ヒト哺乳動物である、請求項１１〜１３のいずれかに記載の方法。
- 非ヒト対象に投与する前に細菌を死滅させる、請求項１１〜１４のいずれかに記載の方法。
- 細菌が非ヒト対象で複製することができない、請求項１１〜１５のいずれかに記載の方法。
- 非ヒト対象に、請求項１〜１０のいずれかに記載のワクチンを投与する工程を含む、鞭毛細菌による感染に付随する罹病率を非ヒト対象で低下させる方法であって、前記ワクチンが前記鞭毛細菌に対する非ヒト対象の免疫応答を強化するために有効な量で投与される、前記罹病率を低下させる方法。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98380307P | 2007-10-30 | 2007-10-30 | |
| PCT/US2008/081813 WO2009059018A1 (en) | 2007-10-30 | 2008-10-30 | Compositions and methods of enhancing immune responses to flagellated bacterium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011502165A JP2011502165A (ja) | 2011-01-20 |
| JP2011502165A5 true JP2011502165A5 (ja) | 2011-12-22 |
Family
ID=40591464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532246A Pending JP2011502165A (ja) | 2007-10-30 | 2008-10-30 | 鞭毛細菌に対する免疫応答を強化する組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9125854B2 (ja) |
| EP (1) | EP2214840B1 (ja) |
| JP (1) | JP2011502165A (ja) |
| CN (1) | CN102037135A (ja) |
| AU (1) | AU2008318615A1 (ja) |
| BR (1) | BRPI0818736A2 (ja) |
| CA (1) | CA2704457A1 (ja) |
| HK (1) | HK1146644A1 (ja) |
| NZ (1) | NZ585776A (ja) |
| WO (1) | WO2009059018A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101522210B (zh) * | 2006-09-18 | 2017-03-22 | 阿肯色大学评议会 | 增强免疫应答的组合物和方法 |
| US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
| PL2214701T3 (pl) | 2007-11-01 | 2017-01-31 | The Board Of Trustees Of The University Of Arkansas | Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria |
| US8647642B2 (en) | 2008-09-18 | 2014-02-11 | Aviex Technologies, Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment |
| UA110024C2 (uk) | 2010-01-21 | 2015-11-10 | Вакцинний вектор і спосіб посилення імунної відповіді | |
| KR102007132B1 (ko) | 2010-06-09 | 2019-08-05 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 캄필로박터 감염을 감소시키기 위한 백신 및 방법 |
| EP2934512B1 (en) | 2012-12-18 | 2021-11-24 | Kotzker Consulting LLC | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
| NZ711019A (en) | 2013-02-14 | 2019-07-26 | Univ Arkansas | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
| EP2968423A4 (en) | 2013-03-15 | 2016-11-09 | Univ Arkansas | COMPOSITIONS AND METHODS FOR INCREASING IMMUNE REACTIONS AGAINST ENTERAL PATHOGENES |
| CN104789583A (zh) * | 2014-01-20 | 2015-07-22 | 华中农业大学 | 一种人源产肠毒素大肠杆菌鞭毛蛋白2FliC融合蛋白及其应用 |
| CN104328136B (zh) * | 2014-10-03 | 2018-04-17 | 哈尔滨博翱生物医药技术开发有限公司 | 鸡新城疫病毒毒株rClone30‑fliC的制备及其在鸡新城疫病防治中的应用 |
| BR112018072592A2 (pt) | 2016-05-03 | 2019-04-16 | The Board Of Trustees Of The University Of Arkansas | vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US20200216506A1 (en) * | 2017-05-12 | 2020-07-09 | Children's Medical Center Corporation | Nucleic acids that manipulate immune pathways |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4420497A (en) * | 1981-08-24 | 1983-12-13 | Fairchild Camera And Instrument Corporation | Method of detecting and repairing latent defects in a semiconductor dielectric layer |
| US4510674A (en) * | 1982-10-21 | 1985-04-16 | Sovonics Solar Systems | System for eliminating short circuit current paths in photovoltaic devices |
| KR100240182B1 (ko) | 1991-03-05 | 2000-01-15 | 레슬리 제인 에드워즈 | 재조합 단백질을 발헨하는 약독해진 박테리아를 함유하는 백신 |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
| US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
| DK0822199T3 (da) | 1991-10-25 | 2004-12-27 | Amgen Inc | N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf |
| DE69322092T2 (de) | 1992-09-04 | 1999-07-15 | University Of Saskatchewan, Saskatoon | Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien |
| AU1059095A (en) | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
| JP3657271B2 (ja) | 1995-03-01 | 2005-06-08 | イミュネックス・コーポレーション | 病原性または日和見感染性生物に感染した哺乳動物の治療のための組成物 |
| AU693713B2 (en) | 1995-06-07 | 1998-07-02 | Immunex Corporation | CD40L mutein |
| US5800632A (en) * | 1995-09-28 | 1998-09-01 | Canon Kabushiki Kaisha | Photovoltaic device and method for manufacturing it |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US6306387B1 (en) | 1997-05-29 | 2001-10-23 | The Research Foundation Of State University Of New York | Antigen delivery system |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| CA2223225A1 (en) | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
| CA2313805A1 (en) | 1997-12-19 | 1999-07-01 | Immunex Corporation | Method for reducing susceptibility to hiv infection |
| GB9806449D0 (en) | 1998-03-25 | 1998-05-27 | Peptide Therapeutics Ltd | Attenuated bacteria useful in vaccines |
| US6190669B1 (en) | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| EP1108034B1 (en) | 1998-09-04 | 2008-08-06 | Emergent Product Development UK Limited | Attenuated salmonella spi2 mutants as antigen carriers |
| US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| CA2369820A1 (en) | 1999-04-16 | 2000-10-26 | Frank Dicker | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| EP1067194A1 (en) | 1999-04-16 | 2001-01-10 | F. Hoffmann-La Roche Ag | Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
| WO2001026608A2 (en) | 1999-10-14 | 2001-04-19 | Ledbetter Jeffrey A | Dna vaccines encoding antigen linked to a domain that binds cd40 |
| MXPA00012796A (es) | 1999-12-28 | 2002-05-23 | Akzo Nobel Nv | Vacuna de salmonella. |
| EP1255560B1 (en) | 2000-02-02 | 2008-10-29 | UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE | Cd40 ligand adjuvant for respiratory syncytial virus vaccine |
| ATE300949T1 (de) | 2000-03-17 | 2005-08-15 | Pharmacia & Upjohn Co Llc | Ssa inaktivierte salmonella impfstoffe |
| GB0015426D0 (en) | 2000-06-24 | 2000-08-16 | Univ Southampton | Method for generating soluble highly multimeric proteins |
| AU2002221780A1 (en) | 2000-10-31 | 2002-05-15 | F.Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| US8703146B2 (en) | 2001-04-20 | 2014-04-22 | Institute For Systems Biology | Toll-like receptor 5 ligands and methods of use |
| EP2687593A1 (en) | 2001-05-15 | 2014-01-22 | Ortho-McNeil Pharmaceutical, Inc. | Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| US6923958B2 (en) | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
| EP1499191B1 (en) * | 2002-04-15 | 2012-05-09 | Washington University in St. Louis | Regulated attenuation of live vaccines to enhance cross protective immunogenicity |
| US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| US20060014248A1 (en) | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| US20050181994A1 (en) | 2003-01-06 | 2005-08-18 | Xencor, Inc. | Novel variants of CD40L protein |
| US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| EP1673389A2 (en) | 2003-10-10 | 2006-06-28 | Xencor Inc. | Novel variants of cd40l protein |
| WO2005058950A2 (en) | 2003-12-11 | 2005-06-30 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
| US8828957B2 (en) | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
| US7098058B1 (en) * | 2004-01-15 | 2006-08-29 | University Of Toledo | Photovoltaic healing of non-uniformities in semiconductor devices |
| JP2008508855A (ja) | 2004-04-27 | 2008-03-27 | インターツェル・アクチェンゲゼルシャフト | Ｔｄ抗原 |
| WO2005113598A2 (en) | 2004-05-21 | 2005-12-01 | Xencor, Inc. | Tnf super family members with altered immunogenicity |
| WO2006034268A2 (en) * | 2004-09-20 | 2006-03-30 | Georgia Tech Research Corporation | Photovoltaic cell |
| US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
| CN101080487B (zh) | 2004-10-07 | 2012-11-14 | 阿戈斯治疗公司 | 成熟树突细胞组合物及其培养方法 |
| WO2006105972A1 (en) | 2005-04-07 | 2006-10-12 | Universite Libre De Bruxelles | Transgenic organism expressing cd40l and uses thereof |
| US20060286074A1 (en) | 2005-05-31 | 2006-12-21 | Yucheng Tang | Methods for immunotherapy of cancer |
| JP2009511452A (ja) | 2005-10-07 | 2009-03-19 | プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ | Ｃ型肝炎の予防および治療のための免疫刺激物質の組合せ |
| EP1951862B1 (en) | 2005-11-07 | 2013-07-24 | MicroVAX, LLC | Cd40 ligand fusion protein vaccine |
| WO2007054658A1 (en) | 2005-11-14 | 2007-05-18 | King's College London | Control of immune responses |
| WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| US8802419B2 (en) | 2006-03-02 | 2014-08-12 | University Of Massachusetts | Modified pathogens for use as vaccines |
| US20070227586A1 (en) * | 2006-03-31 | 2007-10-04 | Kla-Tencor Technologies Corporation | Detection and ablation of localized shunting defects in photovoltaics |
| CN101522210B (zh) | 2006-09-18 | 2017-03-22 | 阿肯色大学评议会 | 增强免疫应答的组合物和方法 |
| WO2008109825A2 (en) | 2007-03-08 | 2008-09-12 | Mayo Foundation For Medical Education And Research | Inducing immune-mediated tumor cell death |
| PL2214701T3 (pl) | 2007-11-01 | 2017-01-31 | The Board Of Trustees Of The University Of Arkansas | Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria |
-
2008
- 2008-10-30 NZ NZ585776A patent/NZ585776A/en unknown
- 2008-10-30 CA CA 2704457 patent/CA2704457A1/en not_active Abandoned
- 2008-10-30 AU AU2008318615A patent/AU2008318615A1/en not_active Abandoned
- 2008-10-30 US US12/740,631 patent/US9125854B2/en active Active
- 2008-10-30 BR BRPI0818736A patent/BRPI0818736A2/pt not_active IP Right Cessation
- 2008-10-30 CN CN2008801169113A patent/CN102037135A/zh active Pending
- 2008-10-30 WO PCT/US2008/081813 patent/WO2009059018A1/en active Application Filing
- 2008-10-30 EP EP20080832781 patent/EP2214840B1/en active Active
- 2008-10-30 JP JP2010532246A patent/JP2011502165A/ja active Pending
-
2011
- 2011-01-26 HK HK11100779.4A patent/HK1146644A1/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011502165A5 (ja) | ||
| JP2011503003A5 (ja) | ||
| Amalaradjou et al. | Bioengineered probiotics, a strategic approach to control enteric infections | |
| JP6687585B2 (ja) | 免疫応答を増強するワクチンベクターおよび方法 | |
| JP2016515133A5 (ja) | ||
| US11013792B2 (en) | Compositions and methods of enhancing immune responses to enteric pathogens | |
| JP2010516713A5 (ja) | ||
| JP5245092B2 (ja) | 百日咳に対する単一用量ワクチンとしての生弱毒化ボルデテラ株 | |
| JP2013518052A5 (ja) | ||
| JP2010011868A5 (ja) | ||
| JP6532407B2 (ja) | アイメリアに対する免疫応答を強化するか又はアイメリア感染症を制限する組成物及び方法 | |
| EP2857038A3 (en) | Compositions and methods of enhancing immune responses | |
| RU2009142976A (ru) | Вакцина на основе слитого белка | |
| MX2012014395A (es) | Vacuna y metodos para reducir una infeccion por campylobacter. | |
| Sleator | Designer probiotics: Development and applications in gastrointestinal health | |
| JP2012516140A5 (ja) | ||
| CN111182920A (zh) | 针对抗原的保护性免疫的诱导 | |
| Pellissery et al. | Lactic acid bacteria as mucosal delivery vaccine | |
| WO2018147265A1 (ja) | 病原性グラム陰性菌に対するワクチン | |
| TWI583697B (zh) | Novel binding of the cell wall of the peptide sequence | |
| CN101400783B9 (zh) | 包特氏菌减毒活菌株作为抗百日咳的单剂量疫苗 | |
| WO2013164334A1 (en) | Escherichia coli vaccine | |
| Chodaczek et al. | Lactoferrin-monophosphoryl lipid a complex enhances immunity of mice to Plesiomonas shigelloides CNCTC 138/92 | |
| NZ618243A (en) | Group a streptococcus multivalent vaccine | |
| NZ711761B2 (en) | Compositions and methods of enhancing immune responses to enteric pathogens |